The 36-month beta value for ABUS is also noteworthy at 1.23. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABUS is 148.66M, and at present, short sellers hold a 8.64% of that float. The average trading volume of ABUS on June 27, 2025 was 937.24K shares.
ABUS) stock’s latest price update
The stock of Arbutus Biopharma Corp (NASDAQ: ABUS) has decreased by -4.19 when compared to last closing price of 3.34.Despite this, the company has seen a loss of -7.78% in its stock price over the last five trading days. globenewswire.com reported 2025-06-25 that Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China
ABUS’s Market Performance
Arbutus Biopharma Corp (ABUS) has experienced a -7.78% fall in stock performance for the past week, with a -7.25% drop in the past month, and a -4.48% drop in the past quarter. The volatility ratio for the week is 5.08%, and the volatility levels for the past 30 days are at 3.84% for ABUS. The simple moving average for the past 20 days is -7.00% for ABUS’s stock, with a -8.80% simple moving average for the past 200 days.
Analysts’ Opinion of ABUS
Many brokerage firms have already submitted their reports for ABUS stocks, with Jefferies repeating the rating for ABUS by listing it as a “Buy.” The predicted price for ABUS in the upcoming period, according to Jefferies is $5 based on the research report published on February 02, 2022 of the previous year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $5. The rating they have provided for ABUS stocks is “Hold” according to the report published on February 25th, 2021.
H.C. Wainwright gave a rating of “Buy” to ABUS, setting the target price at $10 in the report published on December 17th of the previous year.
ABUS Trading at -4.37% from the 50-Day Moving Average
After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.28% of loss for the given period.
Stock Fundamentals for ABUS
Current profitability levels for the company are sitting at:
- -14.28 for the present operating margin
- -0.51 for the gross margin
The net margin for Arbutus Biopharma Corp stands at -11.96. The total capital return value is set at -0.94. Equity return is now at value -79.02, with -57.29 for asset returns.
Based on Arbutus Biopharma Corp (ABUS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -49.37. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -755.4.
Currently, EBITDA for the company is -68.4 million with net debt to EBITDA at 0.48. When we switch over and look at the enterprise to sales, we see a ratio of 90.11. The receivables turnover for the company is 5.42for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.01.
Conclusion
In summary, Arbutus Biopharma Corp (ABUS) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
